Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Anti-Inflammatory Effect of Simvastatin in Hemodialysis Patients

Heshmatollah Shahbazian 1 , Afagh Atrian 1 , Leila Yazdanpanah 1 , * , Gholam Reza Lashkarara 1 and Azita Zafar Mohtashami 1
Authors Information
1 Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: February 01, 2015, 10 (1); e17962
  • Published Online: February 1, 2015
  • Article Type: Research Article
  • Received: February 1, 2014
  • Revised: May 25, 2014
  • Accepted: September 6, 2014
  • DOI: 10.17795/jjnpp-17962

To Cite: Shahbazian H, Atrian A, Yazdanpanah L, Lashkarara G R, Zafar Mohtashami A. Anti-Inflammatory Effect of Simvastatin in Hemodialysis Patients, Jundishapur J Nat Pharm Prod. 2015 ; 10(1):e17962. doi: 10.17795/jjnpp-17962.

Abstract
Copyright © 2015, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol. 2003; 16(2): 238-44[PubMed]
  • 2. Navarro JF, Mora C, Muros M, Garcia-Idoate G. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin Pract. 2003; 95(4)-35[PubMed]
  • 3. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G, et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005; 68(1): 237-45[DOI][PubMed]
  • 4. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002; 39(6): 1213-7[DOI][PubMed]
  • 5. Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, et al. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scand J Urol Nephrol. 2005; 39(6): 503-10[DOI][PubMed]
  • 6. Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler Suppl. 2006; 7(1): 31-5[DOI][PubMed]
  • 7. D'Amico G. Statins and renal diseases: from primary prevention to renal replacement therapy. J Am Soc Nephrol. 2006; 17(4 Suppl 2)-52[DOI][PubMed]
  • 8. Sirken G, Cheng KS, Rasib R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIOJ. 2003; 49: 422-5
  • 9. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis. 2004; 43(3): 471-8[PubMed]
  • 10. Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant. 2006; 21(2): 337-44[DOI][PubMed]
  • 11. Tsirpanlis G, Boufidou F, Manganas S, Chantzis K, Bleta A, Stamatelou K, et al. Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients. Blood Purif. 2004; 22(6): 518-24[DOI][PubMed]
  • 12. Judith M. Atorvastatin and Simvastatin in patients on hemodialysis. J Nephrol. 2003; 16(2): 238-44
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments